Co-infection of HIV and HCV Among Patients Under Antiretroviral Treatment: Insights from Selected Healthcare Facilities in Ilorin, Nigeria - Takeaways - MDSpire

Co-infection of HIV and HCV Among Patients Under Antiretroviral Treatment: Insights from Selected Healthcare Facilities in Ilorin, Nigeria

  • By

  • Felicia E. Williams

  • Jane-Frances I. John-Benson

  • Winifred D. Giwa

  • David U. Adje

  • Louis O. Odeigah

  • Chinonyerem O. Iheanacho

  • Isabel N. Aika

  • January 22, 2026

  • 0 min

Share

  • 1

    HIV/HCV co-infection significantly complicates treatment and increases disease burden compared to mono-infections.

  • 2

    In Nigeria, HIV/HCV co-infection prevalence varies, with recent studies showing rates from 0% to 23.2% in different regions.

  • 3

    Co-infected patients face higher mortality rates from liver diseases and greater hepatotoxicity from antiretroviral therapy.

  • 4

    Routine HCV screening for people living with HIV is crucial for early detection and effective management of co-infection.

  • 5

    This study aims to update the prevalence data of HIV/HCV co-infection in Ilorin, Nigeria, to inform public health strategies.

Original Source(s)

Co-infection of HIV and HCV Among Patients Under Antiretroviral Treatment: Insights from Selected Healthcare Facilities in Ilorin, Nigeria

  • by Felicia E. Williams, Jane-Frances I. John-Benson, Winifred D. Giwa, David U. Adje, Louis O. Odeigah, Chinonyerem O. Iheanacho, Isabel N. Aika

  • January 22, 2026

Related Content

Human serum-supplemented cell culture conditions improve xenobiotic metabolism in hepatoma cell lines HepG2 and Huh7

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral RNA on the DASH Rapid Polymerase Chain Reaction System